Related Experiment Video

Updated: Jul 12, 2026

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

p53 Immunohistochemistry Is a Reliable Method for Assessing TP53 Allelic and Functional Status in TP53-Mutated Cases

Hong Fang1, Joseph D Khoury2, Zhenya Tang2

  • 1Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

American Journal of Hematology
|July 10, 2026
PubMed
Abstract

No abstract available in PubMed .

Keywords:
TP53allelic statuscomplex karyotypeimmunohistochemistrymutation

More Related Videos

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Purification of Ubiquitinated p53 Proteins from Mammalian Cells
10:55

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

Related Experiment Videos

Last Updated: Jul 12, 2026

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Purification of Ubiquitinated p53 Proteins from Mammalian Cells
10:55

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...

Articles linked to this work by shared authors, journal, and citation graph.

Myeloid Neoplasm with Eosinophilia Harboring a Novel CCDC6::PDGFRB fusion: Diagnostic Challenge and Therapeutic Implications.

Annals of clinical and laboratory science·2026

Predictors of survival in adults with B-cell acute lymphoblastic leukemia treated with blinatumomab and/or inotuzumab ozogamicin in first salvage.

Leukemia·2026

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy.

Cancer·2026

Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial.

Blood cancer discovery·2026

Overcoming menin inhibitor resistance in AML cells with combinations including BET proteins and a dual BRG1/BRM inhibitor.

Blood·2026

Chromosome 1q Gain Defines a Plasma Cell-Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival.

American journal of hematology·2026

Myeloma Elderly Prognostic Score (MEPS): A Proposed Prognostic Score Integrating Age, Renal Function, Performance Status, and Ultra-High-Risk Cytogenetics.

American journal of hematology·2026

Older Age, STAG2, and DNMT3A Mutations Predict Superior Posttransplant Survival in Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents.

American journal of hematology·2026

Mitigating HLA Disparity in AML Transplantation: Comparable Outcomes After Haploidentical and 9/10 Mismatched Unrelated Donor Transplantation With Treosulfan and PTCy.

American journal of hematology·2026

Clinically Relevant Outcomes With Romiplostim in Patients With Solid Tumors and Persistent Chemotherapy Induced Thrombocytopenia.

American journal of hematology·2026

Multiple Myeloma: 2026 Update on Diagnosis, Risk-Stratification and Management.

American journal of hematology·2026

Understanding Mycobacterium tuberculosis host immune responses and identifying synergistic autophagy-inducing compounds as potential nanomedicines for tuberculosis treatment.

Nanomedicine (London, England)·2026

Tumor Budding Unveiled: Clinicopathological Correlations and Survival Insights From a Tertiary Care Cancer Center of India.

International journal of breast cancer·2026

Regulatory T cells in the bladder cancer tumor microenvironment: mechanisms of immune suppression and therapeutic opportunities.

Frontiers in molecular biosciences·2026

Case Report: Pulmonary fibroleiomyomatous hamartoma presenting as a giant exophytic multilocular cystic lesion.

Frontiers in medicine·2026

A locally deployed large language model for pathology-informed and nurse-reviewed communication support in bladder cancer immunotherapy.

Frontiers in medicine·2026

Inflammatory myofibroblastic tumor of the larynx: a case report.

Frontiers in oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us